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Abstract
Background: The aim of this study was to examine potential therapeutic effect of the two NO
donors NCX 2057 (3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid) 4-(nitrooxy)butyl ester)
and SNP (sodium nitroprusside) on the early allergic airway response in the peripheral lung.
Methods: The experiments were performed in guinea pig lung parenchyma (GPLP) derived from
ovalbumin (OVA) sensitized guinea pigs. The effects of NCX 2057 and SNP were evaluated by
contractile responses and mediator release during OVA challenge. The generation of nitrite and
nitrate was assessed by chemiluminescence. Statistical analysis was evaluated by ANOVA.
Results: Cumulatively increasing concentrations of OVA (1–10,000 ng/ml) induced concentration-
dependent contractions of the GPLP that were reduced by NCX 2057 (100 μM, p < 0.001) and
SNP (100 μM, p < 0.05). Antigen-induced eicosanoid release was decreased by NCX 2057 (100
μM, p < 0.001) but not by SNP (100 μM), whereas the release of histamine was reduced by SNP
(100 μM, p < 0.001) but not by NCX 2057 (100 μM). In addition, NCX 2057 (0.1–100 μM), but
not SNP (0.1–100 μM), relaxed leukotriene D4 (10 nM) precontracted GPLP (p < 0.01). The
guanylyl cyclase inhibitor ODQ had no effect on the NCX 2057 mediated relaxation. SNP released
significantly less nitrite than NCX 2057.
Conclusion:  Although both SNP and NCX 2057 reduced the release of pro-inflammatory
mediators, their profiles were distinctly different. Furthermore, NCX 2057 also induced smooth
muscle dilation in the GPLP. The findings point to specific anti-inflammatory effects of different NO
donors in the peripheral lung tissue.
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Background
Administration of exogenous nitric oxide (NO) and nitro
vasodilators has received considerable attention, mainly
due to their therapeutic ability and haemodynamic
effects, and are well established drugs for treatment of car-
diac disorders [1,2]. Exogenous NO also has the ability to
exert bronchodilatory effects in bronchial asthma [3] and
NO is used in the treatment of preterm children to
improve lung capacity [4]. However, the effect of NO
donors during the early allergic airway response requires
further evaluation, especially in the distal lung.
In the peripheral lung, the release of histamine and
eicosanoids (leukotrienes and prostaglandins) from acti-
vated inflammatory cells, such as mast cells and macro-
phages, may contribute significantly to the symptoms of
allergic rhinitis and asthma [5-8]. In the airways, mast
cells and alveolar macrophages also represent a major
source of NO [2,9-11], which may act both directly on
smooth muscle cells and in an autocrine fashion to sup-
press allergen-induced responses, as release of histamine
[12] and leukotriene synthesis [13]. Inhibitors of NO syn-
thases have been shown to enhance antigen-induced
bronchoconstriction in sensitized guinea pigs by
increased generation of leukotrienes [14].
The aim of this study was therefore to examine the role of
NO donors in antigen-induced responses in the periph-
eral part of the lung. Thus, two structurally different NO
donors, NCX 2057 (3-(4-Hydroxy-3-methoxyphenyl)-2-
propenoic acid) 4-(nitrooxy) butyl ester) [15] and SNP
(sodium nitroprusside; Na2  [Fe(CN)5NO]*2H20) were
used (fig 1). The substance NCX 2057 (fig 1a) belongs to
a newly class of developed NO donors that are chemically
conjugated to a variety of therapeutic drugs, including the
anti-histamine cetirizine [15] and NSAIDs [16]. NCX
2057 has also been shown to have anti-inflammatory
properties [17]. Therefore, the parent compound of NCX
2057, ferulic acid, was also studied, as this substance has
been described to have anti-inflammatory potential [18].
The other NO donor, SNP (fig 1b), is a vasodilator, used
in cardiovascular treatments to lower blood pressure or to
improve cardiac function [19].
The experiments were performed in actively sensitized
guinea pig lung parenchyma (GPLP), an in vitro model for
antigen-induced contractions [20]. Recent studies of anti-
gen-induced airway constriction in the guinea pig lung
indicate that the responses to allergen in humans are sim-
ilar to the responses obtained in the guinea pig [21,22],
since histamine, cysteinyl-leukotrienes (CysLTs) and sev-
eral prostanoids contribute to the antigen-induced airway
constriction in these particular species. The hypothesis to
be tested was that NO donors in the peripheral lung may
affect antigen-induced contractions either generally by
dilatation of smooth muscle tissue or specifically via
actions on release of histamine or eicosanoids. The data
revealed that the tested NO donors SNP and NCX 2057
acted as inhibitors of allergen-induced mediator release.
Methods
Animals and OVA-sensitization
Male Dunkin Hartley guinea pigs (300–350 g b.w.) were
sensitized to Chicken Egg Albumin (OVA) at least four
weeks prior to experiments [14]. The study was approved
by the regional committee of animal experimentation eth-
ics (N127/04).
Lung parenchymal strips and organ bath experiments
The animals were sacrificed by an overdose of inhaled
CO2 and the heart-lung-package was quickly removed and
placed in ice-cold Tyrode's solution (prepared each day,
containing NaCl 149.2 mM, KCl 2.7 mM, NaHCO3 11.9
mM, glucose 5.5 mM, CaCl2 1.8 mM, MgCl2 0.5 mM,
NaH2PO4 0.4 mM). The lung parenchyma was cut parallel
to the peripheral margins, yielding four to eight strips,
each having a size of 2 × 2 × 20 mm and a weight of
approximately 60 mg. The lung parenchymal strips were
set up at a resting tension of 2.5 mN (0.25 g) in 5 ml organ
baths filled with Tyrode's solution, bubbled with carbo-
gen gas (6.5% CO2 in O2) to keep a pH of 7.4 and the tem-
perature was kept at 37°C [14,15]. Changes in smooth
muscle tension, contractions and relaxations, were
recorded via isometric force-displacement transducers
connected to a Grass polygraph and responses were dis-
Chemical structure of the NO donors A, NCX 2057 and B,  SNP Figure 1
Chemical structure of the NO donors A, NCX 2057 
and B, SNP. The arrow indicates cleavage site of NO con-
jugation on substance NCX 2057.
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played by using the IOX data acquisition system (EMKA,
France). Data were analyzed by the software program
Dataanalyst (EMKA, France). After an equilibration
period of 90 min and washes each 15 min, histamine (1–
30 μM) was added cumulatively as a control of the GPLP
reactivity. Preparations displaying contraction responses
less than 1.0 mN to the highest concentration of hista-
mine were excluded from further experiments. Another
wash and equilibration period between histamine and
treatment period was performed. All drugs were given 15
min before the challenges.
OVA was added as cumulative challenge of increasing
concentrations (1–10,000 ng/ml) every 10 min without
changing bath fluid. The cumulative OVA concentrations
were chosen to generate a concentration-response curve
with no contractions at the lowest dose of 1 ng/ml and
maximum contractions at the final dose of 10,000 ng/ml
OVA. For study of smooth muscle contractions, the GPLP
was contracted with cumulative doses of LTD4 (0.1–100
nM). 10 nM of LTD4 generated a 50% contraction of the
GPLP and this EC50 dose was chosen for studies of smooth
muscle relaxation. These doses have previously been used
in the GPLP in vitro test system [14,15,20]. The GPLP was
precontracted with LTD4 (10 nM) before cumulative addi-
tion of cGMP analogue 8-Bromo-cGMP, SNP or NCX
2057. cGMP-dependent relaxation was evaluated by the
addition of the guanylyl cyclase inhibitor ODQ (30 μM),
which previously has been demonstrated to inhibit
vasodilation induced by NCX 2057 [15]. Maximum con-
tractions of the preparation were determined with hista-
mine (1 mM), acetylcholine (1 mM) and KCl (50 mM) at
the end of each experiment, and other responses were
expressed as percent of maximum contractions.
Measurements of released mediators with enzyme 
immunoassays
A 1-mL aliquot of organ bath fluid was collected from
each organ bath and immediately frozen at -20°C. The
samples were taken at the end of the equilibration period
to obtain basal mediator release from the tissue and at the
obtained contractile plateau after challenge with OVA
1000 ng/ml or at the obtained contractile plateaus after
cumulative doses of OVA (1, 10, 100 and 1000 ng/ml).
Enzyme immunoassay (EIA) analyses of the different
mediators LTB4, CysLTs and the prostanoids thrombox-
ane (TXA2) and prostaglandin (PG) D2 were performed
according to the manufacture's instructions. TXA2 was
measured as the stable metabolite TXB2. PGD2 was meas-
ured as PGD2-mox. The assay detection limits in the bath
fluid levels for the different mediators were 7.8 pg/ml for
TXB2, PGD2 and LTE4 and 3.9 pg/ml for LTB4. Results
below detection limits were set as zero in the statistical
evaluation. The EIA specificity for the different mediators
to interfere with each other was less than 0.01%, with the
exception of the EIA kit for TXB2 cross reacted with PGD2
(0.53%) and with PGE2 (0.09%). The EIA kit for CysLTs
was performed with the CysLT antiserum and the sera
cross reacted with LTC4 (100%) and LTD4 (100%) and
LTE4  (67%). Histamine was measured as previously
described [23,24]. Duplicates of 300 μl were placed in 96-
wells plates and the amount of histamine was analyzed by
a fluorospectrometer at the wavelength 450 nM. The
detection limit for histamine was 3.9 ng/ml.
Measurements of nitrite and nitrate with 
chemiluminescence
Aliquots of bath fluid were collected from the organ bath
for measurements of nitrite and nitrate to obtain an indi-
rect assessment of the NO releasing profile for the NO
donors. To determine the basal production of nitrite and
nitrate in the bath fluid, a sample volume of 200 μl was
withdrawn from each bath before the addition of any
drug. Bath fluid aliquots (200 μl) were then collected at
15, 30, 60, 90 and 120 min after the addition of Tyrode's
solution, DMSO, NCX 2057 (100 μM) or SNP (100 μM).
The amount of nitrite and nitrate was analyzed with a
chemiluminescence method as previously described [25].
Data analysis and statistical procedures
All data are presented as mean ± standard error of the
mean (s.e.m.). Statistical analyses were made for paired
and unpaired observations by Student's t-test or analyses
of variances (ANOVA). All concentration-response curves
were statistically analyzed with two-way ANOVA followed
by the post hoc tests Tukey's t-test or Bonferroni's t-test. A
p-value of less than 0.05 was considered significant.
Drugs and chemical reagents
NaCl, KCl, CaCl2, MgSO4, NaHCO3, KH2PO4 and glucose
were obtained from VWR International (West Chester,
Pennsylvania, USA). Histamine dihydrochloride, acetyl-
choline, ovalbumin (OVA, chicken egg albumin, grade II),
dimethylsulfoxid (DMSO), ferulic acid, ODQ
(1H(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one), 8-
bromo-cGMP and SNP were purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). LTD4 was from Cas-
cade Biochemicals Ltd. (Reading, UK). The EIA kits for
CysLTs, LTB4, TXB2 and PGD2-mox were obtained from
Cayman Chemicals (Ann Arbor, Michigan, USA). NCX
2057 (3-(4-hydroxy-3 methoxyphenyl)-2-propenoic acid
4-(nitroxy) butyl ester) was a kind gift from NicOx
(Bresso, Milan, Italy) and Biolipox (Stockholm, Sweden).
Stock solutions of 1 mM LTD4 were dissolved in 50% eth-
anol-water and then diluted in 20% ethanol-water. The
concentration and purity of LTD4 was checked by UV spec-
troscopy. NCX 2057 and ferulic acid were dissolved in
DMSO. OVA was dissolved in 0.9% NaCl. The other drugs
were dissolved and diluted in Tyrode's solution or milli-
pure water. Dilutions of drugs were freshly made from theRespiratory Research 2009, 10:46 http://respiratory-research.com/content/10/1/46
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stocks for each experiment. The drugs were present in the
organ bath fluid during the remaining experiment. 5 μl of
DMSO was added as a control and did not influence the
baseline or cumulative contractions to OVA.
Results
Effect of SNP and NCX 2057 on antigen-induced 
contractions
Cumulative doses of OVA (1–10,000 ng/ml) induced con-
centration-dependent contractions of the GPLP. Pretreat-
ment with NCX 2057 (1, 10 and 100 μM) concentration-
dependently inhibited the response to OVA (p < 0.05, p <
0.001; fig 2a). Pretreatment with SNP (100 μM) attenu-
ated the contractions to OVA (p < 0.05, fig 2b). Ferulic
acid (100 μM) had no significant effect on the OVA
response (fig 2c).
Effect on the release of mediators upon ovalbumin 
challenge
The mediator release from the lung tissue was analyzed in
the bath fluid to further describe the inhibitory effects of
SNP and NCX 2057 on the OVA-induced contractions.
Basal release in the bath fluid before OVA challenge was
below detection limit for histamine, CysLTs and LTB4,
whereas measurable levels were obtained for TXB2 (46 ±
11 pg/ml) and PGD2 (56 ± 16 pg/ml) (fig 3). After chal-
lenge with OVA (1000 ng/ml) measurable levels were
obtained for all the mediators with the rank order of his-
tamine >> TXB2 > PGD2 > CysLTs > LTB4 (fig 2). SNP (100
μM) significantly reduced the release of histamine (p <
0.001, fig 3a), but did not affect the release of eicosanoids.
NCX 2057 (100 μM) did not change the release of hista-
mine but significantly inhibited the release of eicosa-
noids; LTB4 (p < 0.001, fig 3b), CysLTs (p < 0.001, fig 3c),
PGD2 (p < 0.05, fig 3d) and TXB2 (p < 0.01, fig 3e). Ferulic
acid (100 μM) had no significant effects on the measured
mediators after challenge with OVA 1000 ng/ml (fig 3).
To see any distinction in the release profile between hista-
mine and CysLTs the bath fluid was analysed for all the
cumulative doses of OVA (1–1000 ng/ml). Histamine was
released at low doses of OVA and did not increase signifi-
cantly at higher doses of OVA (fig 4a). In contrast, CysLTs
were dose-dependently generated after cumulative admin-
istration of OVA (fig 4b). The release of histamine was sig-
nificantly inhibited by SNP (100 μM, p < 0.001), whereas
NCX 2057 (100 μM) did not significantly affect this
release (fig 4a). The synthesis of CysLTs was significantly
inhibited by NCX 2057 (100 μM, p < 0.001) after cumu-
lative administration of OVA (fig 4b).
Analysis of nitrate and nitrite generation from SNP and 
NCX 2057
NCX 2057 (100 μM, n = 3) generated nitrite with a peak
of 2280 ± 824 nM after 30 min. The nitrite generation was
at one hour replaced by the generation of nitrate (1597 ±
345 nM) that continuously increased to 5729 ± 466 nM at
two hours (fig 5). SNP (100 μM; n = 3) continuously
released nitrite at around 800 nM for two hours in the
organ bath (fig 5). The generation of nitrate from SNP was
not possible to assess due to unspecific binding during
analysis. The solvent DMSO (5 μl) or Tyrode's buffer did
not generate any nitrite or nitrate (n = 3, fig 5).
Effect as smooth muscle dilators on LTD4-contracted lung 
parenchyma
SNP (0.1–100 μM) displayed no relaxant effect on the
LTD4-induced precontraction, whereas NCX 2057 (0.1–
100 μM) relaxed the lung parenchyma at higher concen-
trations (100 μM, p < 0.01). The cGMP analogue 8-
Bromo-cGMP (0.1–100 μM) concentration-dependently
relaxed the GPLP compared to control (Tyrode's solution)
(p < 0.001). Pretreatment with the guanylyl cyclase inhib-
itor ODQ (30 μM) did not affect the response to either
SNP (1–100 μM, data not shown) or NCX 2057 (1–100
μM) (fig 6). NCX 2057 (1–100 μM) attenuated the con-
tractions to cumulative doses of LTD4 (0.1–100 nM) at the
dose 100 μM (p < 0.001, fig 7). Lower doses of NCX 2057
had no effect on the LTD4-induced contractions.
Discussion
In this study we evaluated the effect of SNP and NCX 2057
during antigen-induced contractions in the peripheral
lung. Our data indicated that the tested NO donors acted
specifically on the release of different antigen-induced
mediators and also differently as smooth muscle dilators.
These data imply that depending on the nature of the NO
donor, specific inhibition of antigen-induced contraction
occurs and results in consistent inhibition of contraction
in response to antigen.
Recent studies of antigen-induced airway constriction in
the guinea pig lung indicate that histamine, CysLTs and
several prostanoids, as PGD2 and TXA2, contribute to the
antigen-induced airway constriction [20-22]. Histamine is
released from granulars in mast cells and basophils and
histamine is an important mediator of the early allergic
airway response and airway inflammation in asthma [5].
Leukotrienes are biosynthesised de novo via 5-lipoxygen-
ase from cell membrane phospholipids in mast cells, eosi-
nophils, neutrophils, basophils and alveolar
macrophages [26]. Prostanoids are generated de novo by
cyclooxygenase (COX) enzymes in most cells [7]. How-
ever, PGD2 is mainly produced by mast cells and is known
as a marker of mast cell activation [27] and associated
with inflammatory conditions [28]. PGD2 is released in
the absence of degranulation, and may be stored or rap-
idly synthesized and released in distinct pathways from
degranulation after IgE ligation. TXA2 is mainly produced
by platelets, macrophages and neutrophils [7]. TXA2 is
increased in the airways of asthmatics after allergen chal-Respiratory Research 2009, 10:46 http://respiratory-research.com/content/10/1/46
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Drug effects on the concentration-response to OVA (1–10,000 ng/ml) in sensitized lung parenchymal strips Figure 2
Drug effects on the concentration-response to OVA (1–10,000 ng/ml) in sensitized lung parenchymal strips. A, 
effect of pretreatment with NCX 2057 (1 μM; n = 5), NCX 2057 (10 μM; n = 6) and NCX 2057 (100 μM; n = 5) compared to 
control (n = 6). B, effect of pretreatment with SNP (100 μM; n = 5) compared to control (n = 10). C, effect of pretreatment 
with 100 μM ferulic acid (n = 7) compared to control (n = 7). Data are expressed as mean ± s.e.m.; statistical analysis was per-
formed by two-way ANOVA. *P < 0.05; ***P < 0.001 vs control.
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Effect of pretreatment with different drugs compared with the control on mediator release from sensitized GPLP after chal- lenge with 1000 ng/ml of OVA Figure 3
Effect of pretreatment with different drugs compared with the control on mediator release from sensitized 
GPLP after challenge with 1000 ng/ml of OVA. Release of A, Histamine (ng/ml); B, CysLTs; C, LTB4; D, PGD2; E, TXB2 
(pg/ml). All samples were collected at baseline and then at the plateau after 1000 ng/ml of OVA. The parenchymal strips had 
been pretreated for 15 min with Tyrode's solution (control), 100 μM SNP (SNP), 100 μM NCX 2057 (2057) and 100 μM feru-
lic acid (FA). All data are expressed as mean ± s.e.m.; statistical analysis was performed by one-way ANOVA. *, P < 0.05; **, P 
< 0.01; ***, P < 0.001 vs control.
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lenge [6]. In the present study, measurements of hista-
mine and eicosanoids in the bath fluid after challenges
with antigen showed that histamine was released in high-
est amounts followed by prostanoids and then leukot-
rienes from the GPLP preparations. However,
leukotrienes are known to be 1000 times more potent
bronchoconstrictors than histamine and the induced con-
tractions are more long lasting [29]. Interestingly, NCX
2057 and SNP had different inhibitory profile on the
measured mediators in the present study. SNP blocked the
release of histamine after challenge with OVA, whereas
NCX 2057 reduced the synthesis of leukotrienes and pros-
tanoids, suggesting that SNP and NCX 2057 may attenu-
ate the activation of inflammatory cells and mediator
release in distinctly different steps. NOx-containing mole-
cules may react with oxygen, superoxides, water, nucle-
otides, metalloproteins, thiols, amines, and lipids to form
products with biochemical actions [2] in the peripheral
lung tissue. NO may also bind to iron-containing
enzymes via nitrosylation and form iron-nitrosyl com-
plexes, resulting in altered enzymatic activity and function
[30]. S-nitrosylation is an important posttranslational
modification that regulates NO transport and cell signal-
ling, and thereby the activity of a vast number of proteins
in different cell types, including mast cells and macro-
phages [30-32], and may be a crucial regulator of airway
responsiveness [33]. There are implications that NO
decrease leukotriene synthesis in mast cells [13] and mac-
rophages [11]. A possible explanation of the inhibitory
effects of NCX2057 in the present study, is therefore that
this lipophilic NO donor has the potential to inhibit de
novo synthesis of leukotrienes and prostanoids via interac-
tion with iron centre in 5-lipoxygenase and cyclooxygen-
ase enzymes [34,35], and via interaction with thiol groups
on LTC4 synthase [34]. In a previous study in the GPLP in
vitro system, inhibition of NO synthases enhanced anti-
gen-induced contractions by increasing the synthesis of
CysLTs in the peripheral lung [14]. The effect of NCX 2057
Effect of pretreatment with SNP (100 μM, n = 4, grey) and NCX 2057 (100 μM, n = 4, black) compared to control (Tyrode's  solution, n = 4, white) on mediator release from sensitized GPLP after cumulative challenge with OVA Figure 4
Effect of pretreatment with SNP (100 μM, n = 4, grey) and NCX 2057 (100 μM, n = 4, black) compared to con-
trol (Tyrode's solution, n = 4, white) on mediator release from sensitized GPLP after cumulative challenge 
with OVA. A, Histamine (ng/ml). B, CysLTs (pg/ml). All samples were collected at baseline and then after 10 min at the pla-
teau of cumulative addition of 1, 10, 100 and 1000 ng/ml OVA. All data are expressed as mean ± s.e.m.; statistical analysis was 
performed by two-way ANOVA.*P < 0.05; ***P < 0.001 vs control.
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on the antigen-induced response could also be explained
by the fact that this molecule is derived from the parent
compound ferulic acid, a substance described to have
anti-inflammatory and anti-oxidant potentials [18,36].
NCX 2057 has previously been implicated to have anti-
inflammatory properties [17]. Nonetheless, in the present
study the ferulic acid substance did not influence either
the antigen-induced contractions or the release of pro-
inflammatory mediators, suggesting that the inhibitory
effect of NCX 2057 is due to its NO conjugation. The other
tested NO donor, SNP, completely reduced the release of
histamine after OVA challenge in this study. Topical
administration of SNP has previously been shown to
reduce histamine-induced plasma exudation both in
guinea pig in vivo and human nasal airways [37] and pre-
vious findings in the rat mast cell confirm that both SNP
and nitrite may inhibit the release of histamine [38,39],
suggesting that SNP has a specific mode of action on
degranulation. SNP was over all less effective than NCX
2057 in this study. Previous studies in the GPLP in vitro
system show that antagonists to the histamine receptor,
such as cetirizine, has very little effect on the early allergic
response in the peripheral lung [15]. This is in line with
A, Generation of nitrite (nM) over two hours in the GPLP  organ bath fluid after addition of SNP (100 μM; n = 3), NCX  2057 (100 μM; n = 3), DMSO (n = 3) or Tyrode's buffer (n =  3) Figure 5
A, Generation of nitrite (nM) over two hours in the 
GPLP organ bath fluid after addition of SNP (100 μM; 
n = 3), NCX 2057 (100 μM; n = 3), DMSO (n = 3) or 
Tyrode's buffer (n = 3). B, Generation of nitrate over two 
hours in the GPLP organ bath fluid after addition of NCX 
2057 (100 μM; n = 3), DMSO (n = 3) or Tyrode's buffer (n = 
3). Data are expressed as mean ± s.e.m.
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the results shown by SNP as a potential histamine inhibi-
tor in these experiments.
SNP did not relax the lung parenchyma whereas higher
concentrations of NCX 2057 (100 μM) induced relaxation
of the smooth muscle tissue in the present study. These
results are in contrast to the previous findings in guinea
pig aorta and pulmonary artery where NCX 2057 induced
vasodilation at much lower concentrations (nM) [15],
supporting the hypothesis that the smooth muscle tissue
in the peripheral lung is less sensitive to NO mediated
dilations. The guanylyl cyclase inhibitor ODQ did not
inhibit the relaxation induced by NCX 2057 despite the
fact that 8-Bromo-cGMP induced strong relaxation in the
GPLP system. This is in contrast to the cGMP-dependent
dilation shown by NCX 2057 in vascular system in a pre-
vious study where ODQ effectively prevented the induced
vasodilation [15]. Nevertheless, nitrovasodilators have
previously been shown to induce smooth muscle relaxa-
tion both dependent and independent via cGMP activa-
tion [40-42].
Although the tested substances are referred as NO donors,
the effect of SNP and NCX 2057 in the peripheral lung
may not only depend on NO generation. The concentra-
tions of the pharmacological agents were higher than are
ordinarily used in vivo and also higher than NO levels pro-
duced in vivo. Measurements of nitrite and nitrate indi-
cated that SNP and NCX 2057 differed notably in their
kinetic profile. NCX 2057 produced significantly more
nitrite than SNP at early timepoints (fig. 4). Nitrite accu-
mulation is generally interpreted as an indicator of NO
release. Thus, this could be a possible explanation for the
decreased effectiveness of SNP relative to NCX 2057 as an
inhibitor of lung contractility. However, it is important to
realize that drugs may be metabolised to nitrate and
nitrite without apparent formation of NO and therefore
one cannot rely completely of nitrate/nitrite measure-
ments as accurate estimates of NO formation. Several
additional factors determine the rate of NO release and
bioavailability of different NO donors including,
lipophilicity, site of NO release, the presence of metal
containing and thiol containing compounds, the stability
of the NO bonds, and the propensity for homolytic vs.
heterolytic cleavage [43]. In contrast to NCX 2057, SNP
also transfers NO+ [43,44], which can react with sulphy-
dryl groups (-SH), to form S-nitrosothiols [45]. The mech-
anisms behind the distinct inhibitory effects of the tested
NO donors on the early allergic airway response need to
be further evaluated in other test systems.
Conclusion
The obtained results point at important differences
between the tested NO donors, making it crucial to care-
fully characterize the profile of a selected NO donor, when
using it as an experimental tool. The data revealed that the
tested NO donors SNP and NCX 2057 acted as specific
inhibitors of allergen-induced mediator release. In con-
trast to SNP, NCX 2057 also induced relaxation in the
GPLP, but not via the cGMP pathway. The findings sup-
port that different NO donors may have specific anti-
inflammatory effects in the peripheral lung tissue and
may facilitate the development of anti-inflammatory ther-
apeutic strategies targeting distinct effects of early allergic
airway response.
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